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Simple Summary: We reviewed the evidence available for postponing or delaying cancer surgery
for localised prostate cancer. Watchful waiting is an acceptable option in low-risk patients. Evidence
is uncertain in postponing surgery, but conservative estimates suggest delays of over 5 months,
4 months, and 30 days for low-, intermediate-, and high-risk patients, respectively, can lead to worse
survival outcomes. Neoadjuvant therapy can shrink the tumours prior to surgery and can be a useful
adjunct in delaying surgery for, at the most, 3 months.
Abstract: External factors, such as the coronavirus disease 2019 (COVID-19), can lead to cancellations
and backlogs of cancer surgeries. The effects of these delays are unclear. This study summarised the
evidence surrounding expectant management, delay radical prostatectomy (RP), and neoadjuvant
hormone therapy (NHT) compared to immediate RP. MEDLINE and EMBASE was searched for
randomised controlled trials (RCTs) and non-randomised controlled studies pertaining to the review
question. Risks of biases (RoB) were evaluated using the RoB 2.0 tool and the Newcastle–Ottawa
Scale. A total of 57 studies were included. Meta-analysis of four RCTs found overall survival and
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cancer-specific survival were significantly worsened amongst intermediate-risk patients undergoing
active monitoring, observation, or watchful waiting but not in low- and high-risk patients. Evidence
from 33 observational studies comparing delayed RP and immediate RP is contradictory. However,
conservative estimates of delays over 5 months, 4 months, and 30 days for low-risk, intermediate-risk,
and high-risk patients, respectively, have been associated with significantly worse pathological and
oncological outcomes in individual studies. In 11 RCTs, a 3-month course of NHT has been shown to
improve pathological outcomes in most patients, but its effect on oncological outcomes is apparently
limited.
Keywords: COVID-19; prostate cancer; radical prostatectomy; treatment delay; surgical waiting time;
active surveillance
1. Introduction
Patients diagnosed with prostate cancer (PCa) can expect disparate times to surgical
treatment based on the risk level of the detected cancer, results of biopsy, threat of metas-
tasis, surgical waiting times, and more recently, external factors such as the coronavirus
disease 2019 (COVID-19) pandemic. Over the fears of patient-to-healthcare transmission
through aerosol or faecal matters during patient care, urological services have been severely
impacted worldwide [1–3] during the pandemic. Furthermore, 30-day mortality of patients
undergoing surgery with confirmed severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection at the time of surgery is as high as 24% [4], which further led to a
predicted 2.3 million cancer surgeries being cancelled or delayed during the pandemic.
During the COVID-19 pandemic, the European Association of Urology (EAU) cate-
gorised PCa into low-, intermediate-, and high-priority based on expected clinical harm
timelines (6+ months for low-priority, 3+ months for intermediate-priority, and <6 weeks
for high-priority) and delays as a result of the COVID-19 pandemic should not exceed
the proposed expected clinical harm timelines [5]. It is also recommended that patients
undergoing active surveillance (AS) for low-risk PCa can have postponed prostate specific
antigen (PSA) screening, confirmatory re-biopsies and digital rectal examinations (DREs).
Active treatment can be deferred for 6–12 months. Similarly, EAU recommends that radical
prostatectomy (RP) can be postponed for both intermediate-risk and high-risk patients
within a safe time limit; however, neo-adjuvant hormone therapy (NHT) is not recom-
mended in intermediate-risk patients but can be used to ease patient anxiety in high-risk
cases [5].
Pandemic aside, delaying prostatectomies allows for flexibility of healthcare resources.
For adequate resource allocation and patient treatment, evaluating the effects of delaying
prostatectomies based on risk category is therefore necessary. Understanding the impact
of prostatectomy delay with respect to the risk level of an individual presentation of PCa
allows personalised care and more reserved treatments for those at low- or intermediate-
risk and better prioritisation of resources for high-risk cases.
While treatment delays or expectant management of months or years for men with
low-risk PCa have not been suggested to negatively impact oncological or pathological
outcomes, non-low-risk PCa present greater challenges as the risks of delaying RP in these
patients are not well established [6–9]. In these patients, prostatectomy delay may suggest
higher risk of oncological progression [10]. NHT has been shown to improve pathological
outcomes in locally advanced PCa patients, but has not been extensively investigated to
delay treatment—it may be utilised during the pandemic [11].
This study aims to evaluate the current literature for evidence surrounding the delay
of RP for patients with different risks of PCa to inform the prioritisation of PCa treatments
both within and outside the context of pandemics and the clearing of cases backlogged.
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2. Materials and Methods
This review was performed according to the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement [12].
2.1. Literature Search
A comprehensive literature search was performed using medical subject headings
(MeSH terms) and keywords on PubMed/MEDLINE, Cochrane Central Register of Con-
trolled Trials (CENTRAL), and Cochrane Database of Systematic Reviews on the 16 May
2020 according to the following search strategy: “(delay OR deferral OR deferred OR
interval OR (neoadjuvant AND (hormone therapy OR complete androgen blockade OR an-
drogen ablation OR hormone treatment OR combined androgen blockade))) AND prostate
cancer AND (surgery OR prostatectomy OR radical prostatectomy).” Additional articles
were also sought from the reference lists of the included studies.
2.2. Selection Criteria
The selection criteria of this review are as follows:
Patients: Men with low-, intermediate- or high-risk PCa.
Intervention: Any delay to RP, including surgical waiting time and NHT; or expectant
management such as AS, active monitoring, watchful waiting, or observation as defined by
the study.
Comparator: Immediate RP from histological diagnosis as defined by the study.
Outcomes: Oncological and pathological outcomes (outlined in Section 2.4).
Study Type: Randomised controlled trials and observational comparative studies.
Non-English studies, animal studies, studies of female patients, and studies without full
text were excluded. Systematic reviews, meta-analyses, letters to the editors, editorials,
and single arm studies were excluded after full-text screening.
2.3. Screening and Data Extraction
All retrieved records were initially screened by title and abstract against the selection
criteria independently by 8 pairs of co-authors. A second screen was then performed (JJL,
WST, JT) to ensure consistency. Finally, eligible articles were screened by full text using the
same manner. Data extraction was then performed independently by six authors (OG, ED,
WT, HK, MP) independently with discrepancy resolved by a 3rd author (WST). A second
extraction was performed by six authors (VC, AA, AN, JK, OB, NW) to ensure consistency.
Data on the studies (first author, year, centre, country, study design), participant demo-
graphics and oncologic characteristics, treatment characteristics, and outcomes and results
were extracted using a piloted, standardised data entry form.
2.4. Data Synthesis and Statistical Analysis
The primary outcome of the study is cancer-specific survival (CSS). Secondary out-
comes include (biochemical) progression-free survival ([BC]PFS), overall survival (OS),
(biochemical), and recurrence-free survival ([BC]RFS). Pathological outcomes such as posi-
tive surgical margin (PSM), organ confinement (OC), positive lymph nodes (PLN), seminal
vesical invasion (SVI), and pathological up/down staging are also evaluated.
As risk levelsof patients included and the time-to-event measurements for most retro-
spective studies are expected to differ, most of the outcomes originating from retrospective
studies are synthesised qualitatively. In the event of three or more randomised stud-
ies reporting the same outcome under similar definition and time-to-event calculations
meta-analysis will be performed. Survival outcomes were meta-analysed and presented
as Hazard Ratios (HRs) and 95% Confidence Intervals (95% CI). Methods validated and
outlined by Tierney et al. [13] were used to estimate HRs when they are not reported, as
recommended by the Cochrane Collaboration [14]. Pathological outcomes are treated as
dichotomous outcomes and reported using Risk Ratios (RR) and 95% CI. The random
effects model (RE) was used for meta-analysis, sensitivity analyses were performed using
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the fixed effects model (FE). The I2 value was used to identify heterogeneity. A I2 value
of 30–60%, 50–90%, and 75–100% corresponds to suggest moderate, substantial, and con-
siderable heterogeneity, respectively [14]. Significance of heterogeneity is defined as a
p-value < 0.10 by Cochran’s Q test.
Risks of biases of observational studies were assessed using the Newcastle Ottawa
Scale (NOS) [15]. RCTs were assessed using the RoB 2.0 tool [16]. The respective risks of
biases summaries are generated using the Robvis tool [17].
3. Results
3.1. Literature Search Results
The PRISMA flow chart is presented in Figure 1. A total of 4120 records were retrieved.
After excluding unrelated studies during initial screening, 143 potential eligible articles
are included for full text review. Finally, a total of 57 studies were included for this review.
Of the 57 studies, 4 and 11 RCTs were included to evaluate expectant managements and
neoadjuvant therapies quantitatively, respectively. Of the remaining 43 non-randomised
studies, 33 reported the effect of delayed RP and 9 reported the effect of NHTs.




Figure 1. PRISMA Flow Chart. 
3.2. Expectant Management 
A total of four trials [6–9] have been identified comparing expectant management, 
active surveillance or watchful waiting with immediate RP. The study details and the risk 
of bias assessments of the four studies are described in Supplementary Table S1 and Sup-
plementary Figure S1, respectively.  
3.2.1. Outcomes in Mixed Risks Patients 
In mixed risks (mixed low-, intermediate- and high-risk) patients, four trials reported 
OS in patients undergoing the two interventions. Overall survival was found to be signif-
icantly worse in patients not undergoing immediate RP (HR 1.21, 95% CI 1.08–1.37, p < 
0.01; (Figure 2). While no significant heterogeneity was observed, the SPCG-4 trial popu-
lation is noted to have a significantly higher proportion of T2 patients (72%), suggesting a 
higher risk population when compared to the other three trials. After removing the SPCG-
4 from meta-analysis, expectant managements no longer have inferior OS when compared 
to immediate RP (HR 1.14, 95% CI 0.99–1.32, p = 0.08; Supplementary Figure S2). Similarly, 
Figure 1. PRISMA Flow Chart.
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3.2. Expectant Management
A total of four trials [6–9] have been identified comparing expectant management,
active surveillance or watchful waiting with immediate RP. The study details and the
risk of bias assessments of the four studies are described in Supplementary Table S1 and
Supplementary Figure S1, respectively.
3.2.1. Outcomes in Mixed Risks Patients
In mixed risks (mixed low-, intermediate- and high-risk) patients, four trials reported
OS in patients undergoing the two interventions. Overall survival was found to be signifi-
cantly worse in patients not undergoing immediate RP (HR 1.21, 95% CI 1.08–1.37, p < 0.01;
(Figure 2). While no significant heterogeneity was observed, the SPCG-4 trial population is
noted to have a significantly higher proportion of T2 patients (72%), suggesting a higher
risk population when compared to the other three trials. After removing the SPCG-4 from
meta-analysis, expectant managements no longer have inferior OS when compared to
immediate RP (HR 1.14, 95% CI 0.99–1.32, p = 0.08; Supplementary Figure S2). Similarly,
amongst the SPCG-4, PIVOT and ProtecT trial, CSS is significantly worse in patients un-
dergoing expectant management when compared to those undergoing immediate RP (HR
1.63, 95% CI 1.26–2.10, p < 0.001; Figure 3). When removing the higher risk patients in the
SPCG-4 trial, CSS amongst patients undergoing expectant management is still significantly
worse compared to those undergoing immediate RP (HR 1.03, 95% CI 1.03–2.44, p = 0.04;
Supplementary Figure S3). PFS was also found to be significantly worse in patients under-
going expectant management compared to those undergoing immediate RP (HR 1.84, 95%
CI 1.34–2.52, p < 0.001; Supplementary Figure S4).
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3.2.2. Outcomes Stratified by Risks
Only two trials stratified patient outcomes into low-risk, intermediate-risk and high
risk. The different classifications of risks are reported in Supplementary Table S1. In
low-risk patients, OS is similar between those undergoing expectant management and
immediate RP (HR 1.31, 95% CI 0.80–2.16, p = 0.29; Supplementary Figure S5a), despite
the SPCG-4 trial having significantly more T2 patients. Similarly, CSS is similar in the
two group of low-risk patients undergoing expectant management or immediate RP (HR
1.31, 95% CI 0.73–2.36, p = 0.36; Supplementary Figure S6a). However, PFS is significantly
worse in patients undergoing expectant management compared to immediate RP (HR
2.11, 95% CI 1.29–3.45, p < 0.01; Supplementary Figure S7a). In intermediate-risk patients,
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however, OS is significantly worse in patients undergoing expectant management when
compared to immediate RP (HR 1.54, 95% CI 1.21–1.98, p < 0.01; Supplementary Figure
S5b). Similarly, CSS is also significantly worse in those undergoing expectant management
(HR 1.51, 95% CI 1.65–3.82, p < 0.01; Supplementary Figure S6b). PFS is also significantly
worse in these patients (HR 2.11, 95% CI 1.45–3.07, p < 0.01; Supplementary Figure S7b). In
high-risk patients, both OS and CSS are similar in the two groups of patients (HR 1.23, 95%
CI 0.95–1.59, p = 0.11; HR 1.18, 95% CI 0.77–1.81, p = 0.45; Supplementary Figures S5c and
S6c). PFS is significantly worse in those undergoing expectant management comparted to
immediate RP (HR 1.47, 95% CI 0.75–2.90, p < 0.01; Supplementary Figure S7c).
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3.3. Observational tudies on Delay of RP
A total of 33 ob erv tional studies were included. The study characteristic , different
definitions o isk l ifi i , and m jor outcomes and risk of bias are outlined in
Supplem ary Tables S2 and S3.
3.3.1. Low Risk Patients
A t tal of 21 studies [10,18–37] reported outco es of delayed RP comp r d to immedi-
ate RP in low-risk patients. Amongst low-risk patients, evidence supporting the delay of RP
are contradictory. Some studies have suggested no effect of any delay on both pathological
and oncological outcomes [19,22,24,32,33,35,36]. However, it was also suggested that a de-
lay of over 5-months may cause significantly worsened pathological and survival outcomes
such as PSA failure-free survival and recurrence free survival [10,21,23,25,27,28,31,36,37].
This could be the result of the heterogeneity of investigated periods of delay from biopsy
or diagnosis, ranging from 3-months to 2-years with various study designs and delay time
cut off intervals.
3.3.2. Intermediate-Risk Patients
A total of 11 studies [10,18–21,24,26,29,30,34,36] reported outcomes of delayed RP com-
pared to immediate RP in intermediate-risk patients. Delaying surgery for intermediate-risk
patients generally leads to significantly worse oncological and pathological outcomes. For
oncological outcomes, the reported minimum delay time to cause significantly worsened
BCRFS is 6-months or more [10,18,20,36]. However, a delay of four months or more was
shown to lead to significantly worse pathological outcomes [10,19,27,36]. There is also
significant heterogeneity of study designs and delay time cut off intervals. The investigated
period of delay from biopsy or diagnosis ranged from 3 months to 9 months.
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3.3.3. High-Risk Patients
A total of 13 studies [10,18–21,24,26,29,30,34,38–41] reported outcomes of delayed
RP compared to immediate RP in high-risk patients. A delay of 30 days or more has
generally found to be associated with worsened BCRFS [10,21,24,34]. However, multiple
studies have also found a delay of up to 180 days not to be associated with worsened
BCRFS [19,38–41]. A delay of 30 days or more is also associated with worsened pathological
outcomes [21] in one study. Some studies have suggested no effect of delay on pathological
outcomes [19,22,40]. There is also a significant heterogeneity of study designs and delay
time cut-off intervals. The investigated period of delay from biopsy or diagnosis ranged
from 1 month to 9 months.
3.4. Use of Neoadjuvant Hormone Replacement Therapy
A total of 21 articles [42–62] reported 11 RCTs comparing the use of NHTs with delayed
RP and immediate RP. All studies reported 3-months courses of NHTs, one study [57]
reported 6-month courses of NHT. The full treatment protocols, outcomes, and risk of biases
are described in Supplementary Table S4 and Supplementary Figure S7. No significant
difference between PSA failure-free survival, overall deaths, and cancer-specific deaths
were found between the two groups. Patients undergoing NHT were found to have
significantly lower rates of PSM (Figure 4), lymph node involvement (Figure 5), and
pathological upstaging at the time of RP. Patients undergoing NHT also have significantly
higher rates of organ confinement (Figure 6), and pathological down-staging at the time
of RP. No differences were found between the two groups for the rates of seminal vesicle
involvement. Results of meta-analyses of all outcomes after 3 months of NHT are reported
in Table 1 and Supplementary Figures S8–S13. One study reported PSM after 6 months of
NHT followed by RP, PSM rate was found to be significantly lower in those receiving NHT
compared to those who did not [57].
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Table 1. Summary of meta-analyses comparing 3 months of NHT and delayed RP versus immediate RP.
Outcome No. of Studies Risk Ratio 95% CI p-Value
Overall Deaths 4 1.30 0.81–2.09 0.28
Cancer-specific Deaths 4 1.25 0.46–3.40 0.66
Positive Surgical Margin 10 0.45 0.37–0.54 <0.01
Organ Confinement 6 1.39 1.10–1.76 <0.01
Lymph node
involvement 6 0.68 0.48–0.97 0.03
Seminal Vesicle
involvement 3 1.02 0.44–2.32 0.97
Pathological Upstaging 2 0.51 0.34–0.76 <0.01
Pathological
Down-staging 3 2.38 1.49–3.78 <0.01
PSA Failure 5 0.96 (HR) 0.78–1.19 0.72
CI: Confidence Interval; PSA: Prostate specific antigen; HR: Hazard Ratio.
4. Discussion
To our knowledge, this is the first study to have systematically summarised the
available evidence to inform the appropriate delay period to avoid worsened oncological
outcomes and potential consequences in delaying RP.
In the four landmark trials [6–9] comparing active monitoring, watchful waiting,
or observation to immediate RP, all but SPCG-4 found similar OS and CSS in patients
undergoing expectant management and immediate RP. In contrast, the SPCG-4 trial found
significantly worse OS and CSS in the watchful waiting arm compared to immediate RP
treatment. The reason could be two-fold. Firstly, the SPCG-4 was conducted in a pre-PSA
test stage and as a result, was prone to significant under-staging compared to ProtecT
and PIVOT. Secondly, up to 76% of all cases in SPCG-4 are cT2 patients, suggesting a
potentially higher risk disease in comparison to other trials. When stratified by risks,
OS and CSS are found to be similar amongst those having immediate RP and expectant
management in low-risks patients and high-risk patients, but not in intermediate-risk
patients. While the results may seem peculiar, it could be likely that patients in the high-
risk groups may have had micro-metastasis at the time of enrolment, likely rendering RP
to be less effective in controlling PCa disease progression. In summary, the three trials have
suggested the oncological safety of active monitoring, watchful waiting or observation
in low-risk patients; however, patients must be followed regularly based on annual DRE,
PSA and repeated biopsy or MRI to avoid progression [72]. Expectant management of
intermediate-risk and high-risk cancer is oncologically unsafe and should be avoided.
In intermediate-risk patients, expectant management should be avoided on the basis
of results from the SPCG-4 and the PIVOT trial. Instead, immediate RP, brachytherapy or
radiotherapy should be considered in this patient in the first instance. However, when
radical treatment is not preferable or suitable, NHT could be considered in such patients.
The results of the EORTC 30,891 trial have suggested significantly better overall survival
in patients undergoing hormonal therapy immediately compared to deferred hormonal
therapy [72].
In high-risk patients, the use of NHT should be considered to delay PCa metastasis
or progression until surgery is deemed safe to perform. As expected, our study has
found oncological outcomes to be similar in those who underwent NHT prior to RP and
those who did not. Furthermore, the pathological outcomes are generally excellent after
NHT, with significantly lower rates of positive surgical margins, lymph node involvement,
pathological upstaging and higher rates of organ confinement and pathological down-
staging. Although encouraging, most available evidence reported a 3-month course of
NHT. There is insufficient evidence to conclude the safety of 6-month NHT courses.
Conclusions and recommendations regarding the optimal timing of delaying surgery
for patients of different PCa risks are difficult to draw. This could be in part due to the
significant heterogeneity amongst non-randomised controlled trials. These retrospective
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studies are hugely limited by different study designs, delay interval cut-offs, lead-time
biases, and inadequate follow-up time (>10 years) to allow for accurate evaluation of
oncological outcomes [73]. The classification of risks is also varied and unclear in most
studies. Nonetheless, a conservative estimate must be taken when decisions are made
to delay surgery for PCa patients and hence a delay of less than 5 months, 4 months,
and 30 days for low-risk, intermediate-risk, and high-risk patients, respectively, may
be acceptable without causing significant harm to the patient without utilising active
surveillance strategies.
Applying the findings of this review to the COVID-19 pandemic, our findings are
grossly in concordance with the EAU COVID-19 recommendations [5]. In low-risk patients,
the EAU recommended deferring confirmatory re-biopsies and any treatments for up to
six months. In intermediate-risk patients, the EAU recommendations suggest treating
before the end of 3 months without the use of any NHT. However, studies included in
our review have suggested a delay in treatment for intermediate-risk patients for over 4
weeks may result in significantly worsened pathological outcomes [10], hence urologists
are advised to carefully balance the risk and benefits of commencing patients on NHT. In
high-risk patients, EAU recommends patients to be treated within 3 months (intermediate
priority) or 6 weeks (high-priority) and not to use NHT to postpone RP. However, our
review suggested a delay of over 30 days may be associated with worsened oncological
outcomes [10,21,24,34]. NHT was also shown to successfully delay surgeries for up to 3
months without increased risk of worsened oncological or pathological outcomes; therefore,
urologists should also be vigilant in deciding the best treatment or any delay for surgery
for high-risk PCa patients.
While our findings are informative, this study is not without limitations. Most studies
included are from the 1980s to the 2000s, before the advancements and popularisation of
PSA screening [74], MRI-targeted biopsy [75], and robotic assisted laparoscopic surgery [76].
Modern drugs for NHT now also include newer gonadotropin-releasing hormone antago-
nists such as degarelix [77]. This may suggest the outcomes of AS, RPs, and NHTs may
have significantly advanced since the studies included in this review were published.
Nonetheless, this study shall provide valuable information to allow better clinical deci-
sion in prioritising patient treatment and backlog clearance in the view of the COVID-19
pandemic.
5. Conclusions
In the case of a delay in surgery, AS and expectant management strategies were found
to be generally safe in low-risk PCa patients. In contrast, in intermediate-risk patients, AS
and expectant management strategies are less safe. A conservative estimate of maximum
acceptable delay treatment for intermediate-risk patients is 4 months, though the evidence
is not the strongest. NHT should also be considered carefully in these patients. In high-risk
patients, AS and expectant management are inappropriate, thus delay for treatment should
be minimised to within 30 days. NHT has been shown to safely delay RP for 3 months
without jeopardising oncological and pathological outcomes, and should be considered
when postponing treatment. However, there is limited evidence to suggest the safety of
NHT therapies for 6 months or longer. Therefore, the use of NHT to delay surgery for over
3 months must be carefully considered.
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